Overview

Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
Phase:
Phase 3
Details
Lead Sponsor:
Vifor Fresenius Medical Care Renal Pharma
Collaborator:
Tigermed Consulting Co., Ltd